Skip to main content

Table 1 Patients’ characteristics

From: Long-term relationship between everolimus blood concentration and clinical outcomes in Japanese patients with metastatic renal cell carcinoma: a prospective study

  Total Continuation Discontinuation or dose reduction by adverse events P value
Patients, n 10 4 6  
Age (years)a 63 (32–74) 61 (51–64) 65 (32–74) 0.3329 b
Male/Female 5/5 1/3 4/2 0.5238 c
Body weight (kg)a 57.7 (46.0–65.8) 58.9 (51.3–63.4) 52.9 (46.0–65.8) 0.4555 b
Body surface area (m2)a 1.57 (1.37–1.74) 1.59 (1.47–1.70) 1.56 (1.37–1.74) 0.7476 b
Body mass index (kg/m2)a 22.1 (16.3–26.2) 23.0 (20.9–26.2) 21.2 (16.3–23.8) 0.2410 b
Aspartate aminotransferase (UI/L)a 27 (16–43) 29 (17–43) 27 (16–42) 0.6689 b
Alanine aminotransferase (UI/L)a 17 (12–47) 26 (12–47) 17 (13–42) 1.0000 b
Serum creatinine (mg/dL)a 0.84 (0.61–1.47) 0.68 (0.61–0.92) 0.99 (0.66–1.47) 0.0691 b
eGFR (mL/min/1.73 m2)a 64.9 (38.2–113.0) 70.0 (64.5–76.0) 50.9 (38.2–113.0) 0.3938 b
ECOG PS, n
0 6 2 4 0.7143 c
1 3 2 1  
2 or more 1 0 1  
Number of prior systemic therapies, n
 2 1 1 0 0.3333 c
 3 7 2 5  
 4 or more 2 1 1  
Initial dose, n
 10 mg/day 8 2 6 0.1333c
 7.5 mg/day 1 1 0  
 5 mg/day 1 1 0  
Everolimus blood concentration on day 8 after starting everolimus administration (ng/mL)a 15.3 (8.1–28.0) 8.2 (8.1–9.8) 18.0 (13.7–28.0) 0.0139b
Everolimus blood concentration just before discontinuation or dose reduction (ng/mL)a 14.8 (6.4–58.4) 9.7 (6.4–17.1) 22.9 (12.5–58.4) 0.0142b
Change of everolimus blood concentration just before discontinuation or dose reduction from day 8 (absolute value, ng/mL)a 1.65 (0.03–36.60) 2.00 (0.03–8.90) 1.40 (0.20–36.60) 0.3374b
  1. eGFR: estimated glomerular filtration rate, ECOG PS: Eastern Cooperative Oncology Group Performance Status, a: Values are reported as median (range), b: Continuous variables evaluated by Wilcoxon rank sum test and c: categorical variables by Fisher exact test